ALNY peers and competitors
Alnylam Pharmaceuticals, Inc. · end-of-day data as of Oct 16, 2026
Alnylam Pharmaceuticals, Inc.
$231.83-14.7%
Buy · 30 analystsPT $374.49 +61.5%
ALNY’s peers by industry and size include Vertex Pharmaceuticals (VRTX), Moderna (MRNA) and Regeneron Pharmaceuticals (REGN). Among these 12 companies ALNY ranks 10th by market cap ($31.02B); its P/E of 39.2 compares with a median of 23.0 for its peers.
Peers by industry and size
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $499.74 | -1.8% | -10.4% | +14.0% | 29.1 | $127B | |
| 2 |  | $218.01 | -7.8% | -7.8% | -25.0% | — | $87.04B | |
| 3 |  | $790.74 | -0.7% | -7.2% | +8.7% | 19.6 | $81.41B | |
| 4 |  | $69.16 | -1.9% | -1.9% | -0.5% | — | $34.16B | |
| 5 |  | $238.97 | -1.3% | -12.7% | +3.7% | 23.0 | $33.61B | |
| 6 |  | $79.38 | +1.2% | -45.2% | +24.2% | 13.1 | $32.78B | |
| 7 |  | $1,622.29 | -1.0% | -1.0% | -7.3% | 36.5 | $32.51B | |
| 8 |  | $86.04 | -1.9% | -6.8% | +12.7% | 34.0 | $32.47B | |
| 9 |  | $69.57 | -1.1% | -21.0% | +20.2% | 20.2 | $31.42B | |
| 10 | | $231.83 | -0.9% | -52.8% | +61.5% | 39.2 | $31.02B | |
| 11 |  | $113.07 | -0.2% | -13.0% | +13.6% | 14.4 | $22.92B | |
| 12 |  | $72.57 | +0.1% | -0.1% | -7.0% | 62.6 | $11.38B |
Data as of Oct 16, 2026 close.